Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Feed Symbols: BCPC

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Earnings
  • News

Balchem Q2 EPS $1.07 Beats $1.00 Estimate, Sales $236.69M Beat $225.49M Estimate

By Bill Haddad
July 29, 7:17 AM
Balchem (NASDAQ:BCPC) reported quarterly earnings of $1.07 per share which beat the analyst consensus estimate of $1.00 by 7 percent. This is a 15.05 percent increase over earnings of $0.93 per share from the same period

BCPC

Read More
57 minute read
  • Intraday Update
  • Markets
  • Movers
  • News
  • Options
  • Trading Ideas

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights
May 6, 12:06 PM
  On Friday, 1043 companies hit new 52-week lows.

AAOI

Read More
12 minute read
  • Intraday Update
  • Markets
  • Movers
  • News
  • Options
  • Trading Ideas

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights
May 3, 12:20 PM
  Tuesday's session saw 211 companies set new 52-week lows.

ACLX

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

HC Wainwright & Co. Maintains Buy on Balchem, Lowers Price Target to $152

By Benzinga Newsdesk
May 2, 6:11 AM
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Balchem (NASDAQ:BCPC) with a Buy and lowers the price target from $155 to $152.

BCPC

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

HC Wainwright & Co. Maintains Buy on Balchem, Lowers Price Target to $155

By Benzinga Newsdesk
March 8, 7:20 AM
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Balchem (NASDAQ:BCPC) with a Buy and lowers the price target from $170 to $155.

BCPC

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Upgrades

Sidoti & Co. Upgrades Balchem to Buy, Announces $175 Price Target

By Benzinga Newsdesk
February 22, 9:59 AM
Sidoti & Co. analyst Mitra Ramgopal upgrades Balchem (NASDAQ:BCPC) from Neutral to Buy and announces $175 price target.

BCPC

Read More
1 minute read
  • Earnings
  • News

Balchem Q4 Adj. EPS $0.85, Inline, Sales $213.13M Beat $198.17M Estimate

By Benzinga Newsdesk
February 18, 8:07 AM
Balchem (NASDAQ:BCPC) reported quarterly earnings of $0.85 per share which met the analyst consensus estimate. This is a 2.41 percent increase over earnings of $0.83 per share from the same period last year. The company

BCPC

Read More
2 minute read
  • Earnings
  • Markets
  • News
  • Pre-Market Outlook

Earnings Scheduled For February 18, 2022

By Benzinga Insights
February 18, 5:19 AM
  Companies Reporting Before The Bell • DraftKings (NASDAQ:DKNG) is likely to report quarterly loss at $0.79 per share on revenue of $445.18 million.

ABR

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

HC Wainwright & Co. Maintains Buy on Balchem, Raises Price Target to $170

By Benzinga Newsdesk
January 10, 7:16 AM
HC Wainwright & Co. maintains Balchem (NASDAQ:BCPC) with a Buy and raises the price target from $160 to $170.

BCPC

Read More
1 minute read
  • Analyst Ratings
  • Downgrades
  • News
  • Price Target

Sidoti & Co. Downgrades Balchem to Neutral, Announces $175 Price Target

By Benzinga Newsdesk
November 29, 11:36 AM
Sidoti & Co. analyst Mitra Ramgopal downgrades Balchem (NASDAQ:BCPC) from Buy to Neutral and announces $175 price target.

BCPC

Posts navigation

1 2 3 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service